NR3C2 and chronic kidney disease: Following the proposal, several placebo-controlled double-blind clinical studies evaluating medications for CKD in diabetes, such as mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 (SGLT2) inhibitors demonstrated correlations between changes in UACR and the incidence of kidney events [13–15].